Adipose tissue insulin resistance, not muscle insulin resistance, is associated with impaired metabolic health in humans.
Fat tissue insulin resistance—not muscle—drives heart disease risk in overweight adults, suggesting we need different treatment approaches for different body tissues.
Using detailed phenotyping (7-point OGTT plus fasting NEFA-based adipose IR index) in 229 overweight/obese adults, this study demonstrates that adipose IR is the predominant driver of systemic cardiometabolic risk, while isolated muscle IR is associated with a relatively preserved metabolic profile. The finding that 42% of participants had discordant IR patterns underscores the need for phenotype-specific therapeutic strategies rather than treating all insulin resistance as equivalent.
What the study was
- Study design
- cross_sectional
- Category
- cardiovascular_metabolic_glp1_sglt2
- Maturity
- Validated
- Journal
- Diabetes Res Clin Pract
Why it surfaced
Mechanistically important finding that dissociates adipose versus muscle IR contributions to cardiometabolic disease—directly relevant to precision treatment selection (e.g., adipose-targeting agents vs. muscle sensitizers) and risk stratification.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.